(Radiology)Multiple recent market withdrawals of drugs that received FDA accelerated approvals have raised concern about the ...

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute ...

as well as cytarabine + daunorubicin, commonly known as 7+3. In the Phase 1a dose escalation portion of the KOMET-007 study, ...

蒽环类药物（anthracyclines）的应用在肿瘤治疗的历史长河中具有里程碑式的意义，其应用范围广泛。尽管在靶向治疗与免疫治疗等新兴疗法日新月异的当下，蒽环类药物依然在多种实体肿瘤及血液恶性肿瘤治疗中发挥着重要作用。那么，蒽环类药物具体涵盖了哪些 ...

Nanoparticles have once again reached the spotlight, this time as a critical tool to combat the spread of covid-19. In this ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...

She initially received oral tretinoin (Vesanoid) followed by daunorubicin on days 1 through 3 and cytarabine on days 1 to 5 (planned treatment is to receive cytarabine for 2 more doses).

Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –– ...

The clinical diagnosis of acute pericarditis is based on simple criteria: typical chest pain, pericardial friction rub (Figure 2), widespread ST-segment elevation (Figure 3) and pericardial ...

Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] Technology appraisal guidance ...

KOMET-007 is a multicenter Phase 1 trial of ziftomenib in combination with standards of care, including cytarabine plus daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with ...